Poor
Mostly Aligned
Patient Risk:
Moderate
Summary
Most interaction/dose-monitoring statements about warfarin are not supported by the provided FDA label excerpts. The excerpted label content includes CYP3A4 metabolism information, but it does not contain warfarin-specific interaction, INR guidance, or warfarin dose adjustment statements, nor specific INR timing or bleeding sign descriptions.
Category Scores
Accurate Statements
Atorvastatin is metabolized by CYP3A4.
Label excerpt Section 12.3: "Metabolism... important role of CYP3A4 suggested..."
Unsupported Statements
Doctors may raise the atorvastatin (Lipitor) dose in patients already taking warfarin.
No warfarin-specific dosing/management guidance is present in the provided label excerpts.
Atorvastatin can interact with warfarin.
The provided label excerpts (Section 7) list interaction risk with fibric acid derivatives, niacin, cyclosporine, and strong CYP3A4 inhibitors, but do not mention warfarin.
The two drugs can interact and INR is monitored closely.
No INR monitoring guidance or warfarin-specific statements appear in the provided excerpts.
Atorvastatin can mildly raise warfarin levels.
No warfarin-level/INR magnitude statements are supported by the provided excerpts.
Raised warfarin levels can push the INR higher.
Warfarin/INR relationship is not described in the provided excerpts.
A higher INR increases bleeding risk.
Bleeding risk tied to INR/warfarin is not described in the provided excerpts.
Warfarin is cleared partly by CYP2C9.
CYP2C9/warfarin clearance is not mentioned in the provided excerpts.
When atorvastatin doses climb, competition for liver enzymes can slow warfarin breakdown.
No warfarin-specific metabolism/competition mechanism is described in the provided excerpts.
Most studies show only a small INR rise with atorvastatin.
No warfarin/INR study results are included in the provided excerpts.
Individual responses to the interaction vary.
No warfarin/INR inter-individual variability is provided in the excerpts.
Dose increases of atorvastatin are done gradually with INR checks.
No warfarin/INR-specific titration/monitoring instructions are provided in the excerpts.
Current prescribing information advises starting or adjusting atorvastatin with frequent INR monitoring until levels stabilize.
No INR monitoring instructions are present in the provided label excerpts.
No blanket rule prohibits higher doses of atorvastatin in this setting.
No warfarin-specific dose restriction is stated in the provided excerpts to support this statement.
Clinicians may adjust warfarin downward if the INR drifts above target.
Warfarin adjustment guidance is not present in the provided excerpts.
Signs of too-high INR include easy bruising.
No INR-specific sign list is included in the provided excerpts.
Signs of too-high INR include prolonged bleeding from cuts.
No INR-specific sign list is included in the provided excerpts.
Signs of too-high INR include dark stools.
No INR-specific sign list is included in the provided excerpts.
Signs of too-high INR include sudden headaches.
No INR-specific sign list is included in the provided excerpts.
Patients report these effects within days of an atorvastatin dose increase.
No warfarin/INR timeline or patient reporting is provided in the excerpts.
Prompt lab testing prevents complications related to high INR.
No warfarin/INR management efficacy statement is present in the excerpts.
INR changes usually appear within three to seven days after a dose change.
No warfarin/INR onset timing is provided in the excerpts.
Most clinicians recheck the INR four to seven days after raising atorvastatin.
No warfarin/INR recheck timing is described in the excerpts.
INR is rechecked again after any further adjustment.
No warfarin/INR recheck schedule is described in the excerpts.
Pravastatin shows less CYP interaction than atorvastatin with warfarin.
The provided excerpts do not include any comparisons between statins or warfarin interactions.
Rosuvastatin shows less CYP interaction than atorvastatin with warfarin.
The provided excerpts do not include any comparisons between statins or warfarin interactions.
Pravastatin sometimes produces smaller INR shifts.
No INR shift outcomes for any statins are included in the excerpts.
Rosuvastatin sometimes produces smaller INR shifts.
No INR shift outcomes for any statins are included in the excerpts.
Pravastatin and rosuvastatin are not universally preferred over atorvastatin in patients taking warfarin.
No label content addresses statin selection specifically for warfarin users.
Choice of statin depends on cholesterol goals, kidney function, and prior response.
The provided excerpts do not provide such warfarin-related statin selection guidance.
Cardiologists or primary-care physicians manage atorvastatin and warfarin dose adjustments.
Practice-setting statements are not contained in the provided label excerpts.
Pharmacists may flag potential interactions in electronic records and suggest INR timing.
Operational guidance is not contained in the provided label excerpts.
Contradictions
Important Omissions
Boxed warning status is not addressed; the provided excerpts do not include a boxed warning section, but the AI statements made multiple safety claims (INR/bleeding risk) without being grounded in label content.
Importance:
Moderate
Label-supported LIPITOR interaction cautions in the provided excerpts focus on drugs increasing statin exposure/myopathy risk (e.g., strong CYP3A4 inhibitors such as clarithromycin, certain HIV protease inhibitors, itraconazole) and do not mention warfarin/INR. The AI did not align to these label-supported interaction categories.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The AI response makes detailed warfarin/INR/bleeding-risk monitoring and symptom claims that are not supported by the provided FDA label excerpts. This mismatch could lead to reliance on unlabelled monitoring/sign guidance.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Aligned
Primary Issue
Warfarin/INR interaction, magnitude, monitoring timing, and INR-related bleeding symptom lists are not supported by the provided LIPITOR label excerpts.
Suggested Improvement
Restrict interaction and monitoring statements to what is present in the provided label excerpts (e.g., CYP3A4 metabolism, increased myopathy risk with strong CYP3A4 inhibitors/cyclosporine and lipid-modifying doses of niacin/fibric acid derivatives). Remove or qualify warfarin/INR-specific claims unless supported by the supplied label text.